Gland Pharma Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: December 4, 2025, 12:58 am

Competitors of Gland Pharma Ltd

All Competitor Stocks of Gland Pharma Ltd

Quarterly Result

Last Updated: August 20, 2025, 10:25 am

Below is a detailed analysis of the quarterly data for Gland Pharma Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 1,039.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,030.00 Cr. (Mar 2025) to 1,039.00 Cr., marking an increase of 9.00 Cr..
• For Expenses, as of Jun 2025, the value is 680.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 636.00 Cr. (Mar 2025) to 680.00 Cr., marking an increase of 44.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 359.00 Cr.. The value appears to be declining and may need further review. It has decreased from 394.00 Cr. (Mar 2025) to 359.00 Cr., marking a decrease of 35.00 Cr..
• For OPM %, as of Jun 2025, the value is 35.00%. The value appears to be declining and may need further review. It has decreased from 38.00% (Mar 2025) to 35.00%, marking a decrease of 3.00%.
• For Other Income, as of Jun 2025, the value is 55.00 Cr.. The value appears strong and on an upward trend. It has increased from 44.00 Cr. (Mar 2025) to 55.00 Cr., marking an increase of 11.00 Cr..
• For Interest, as of Jun 2025, the value is 7.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.00 Cr. (Mar 2025) to 7.00 Cr., marking an increase of 4.00 Cr..
• For Depreciation, as of Jun 2025, the value is 44.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 43.00 Cr. (Mar 2025) to 44.00 Cr., marking an increase of 1.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 362.00 Cr.. The value appears to be declining and may need further review. It has decreased from 391.00 Cr. (Mar 2025) to 362.00 Cr., marking a decrease of 29.00 Cr..
• For Tax %, as of Jun 2025, the value is 26.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 26.00%.
• For Net Profit, as of Jun 2025, the value is 269.00 Cr.. The value appears to be declining and may need further review. It has decreased from 290.00 Cr. (Mar 2025) to 269.00 Cr., marking a decrease of 21.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 16.34. The value appears to be declining and may need further review. It has decreased from 17.60 (Mar 2025) to 16.34, marking a decrease of 1.26.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: October 15, 2025, 5:18 am

Growth

Last Updated: September 5, 2025, 4:45 am

Balance Sheet

Last Updated: December 4, 2025, 1:17 am

Below is a detailed analysis of the balance sheet data for Gland Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

• For Equity Capital, as of Sep 2025, the value is 16.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 16.00 Cr..
• For Reserves, as of Sep 2025, the value is 10,034.00 Cr.. The value appears strong and on an upward trend. It has increased from 9,739.00 Cr. (Mar 2025) to 10,034.00 Cr., marking an increase of 295.00 Cr..
• For Borrowings, as of Sep 2025, the value is 4.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 5.00 Cr. (Mar 2025) to 4.00 Cr., marking a decrease of 1.00 Cr..
• For Other Liabilities, as of Sep 2025, the value is 771.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 661.00 Cr. (Mar 2025) to 771.00 Cr., marking an increase of 110.00 Cr..
• For Total Liabilities, as of Sep 2025, the value is 10,825.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 10,422.00 Cr. (Mar 2025) to 10,825.00 Cr., marking an increase of 403.00 Cr..
• For Fixed Assets, as of Sep 2025, the value is 1,697.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,745.00 Cr. (Mar 2025) to 1,697.00 Cr., marking a decrease of 48.00 Cr..
• For CWIP, as of Sep 2025, the value is 53.00 Cr.. The value appears strong and on an upward trend. It has increased from 42.00 Cr. (Mar 2025) to 53.00 Cr., marking an increase of 11.00 Cr..
• For Investments, as of Sep 2025, the value is 3,293.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,790.00 Cr. (Mar 2025) to 3,293.00 Cr., marking an increase of 503.00 Cr..
• For Other Assets, as of Sep 2025, the value is 5,783.00 Cr.. The value appears to be declining and may need further review. It has decreased from 5,845.00 Cr. (Mar 2025) to 5,783.00 Cr., marking a decrease of 62.00 Cr..
• For Total Assets, as of Sep 2025, the value is 10,825.00 Cr.. The value appears strong and on an upward trend. It has increased from 10,422.00 Cr. (Mar 2025) to 10,825.00 Cr., marking an increase of 403.00 Cr..

Notably, the Reserves (10,034.00 Cr.) exceed the Borrowings (4.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Gland Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 42.40. This value is within the healthy range. It has decreased from 46.90 (Mar 24) to 42.40, marking a decrease of 4.50.
• For Diluted EPS (Rs.), as of Mar 25, the value is 42.40. This value is within the healthy range. It has decreased from 46.90 (Mar 24) to 42.40, marking a decrease of 4.50.
• For Cash EPS (Rs.), as of Mar 25, the value is 65.33. This value is within the healthy range. It has decreased from 67.82 (Mar 24) to 65.33, marking a decrease of 2.49.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 555.40. It has increased from 529.65 (Mar 24) to 555.40, marking an increase of 25.75.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 555.40. It has increased from 529.65 (Mar 24) to 555.40, marking an increase of 25.75.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 340.89. It has decreased from 343.92 (Mar 24) to 340.89, marking a decrease of 3.03.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 89.98. This value is within the healthy range. It has decreased from 91.27 (Mar 24) to 89.98, marking a decrease of 1.29.
• For PBIT / Share (Rs.), as of Mar 25, the value is 67.05. This value is within the healthy range. It has decreased from 70.35 (Mar 24) to 67.05, marking a decrease of 3.30.
• For PBT / Share (Rs.), as of Mar 25, the value is 64.50. This value is within the healthy range. It has decreased from 68.76 (Mar 24) to 64.50, marking a decrease of 4.26.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 42.40. This value is within the healthy range. It has decreased from 46.90 (Mar 24) to 42.40, marking a decrease of 4.50.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 42.40. This value is within the healthy range. It has decreased from 46.90 (Mar 24) to 42.40, marking a decrease of 4.50.
• For PBDIT Margin (%), as of Mar 25, the value is 26.39. This value is within the healthy range. It has decreased from 26.53 (Mar 24) to 26.39, marking a decrease of 0.14.
• For PBIT Margin (%), as of Mar 25, the value is 19.66. This value is within the healthy range. It has decreased from 20.45 (Mar 24) to 19.66, marking a decrease of 0.79.
• For PBT Margin (%), as of Mar 25, the value is 18.92. This value is within the healthy range. It has decreased from 19.99 (Mar 24) to 18.92, marking a decrease of 1.07.
• For Net Profit Margin (%), as of Mar 25, the value is 12.43. This value exceeds the healthy maximum of 10. It has decreased from 13.63 (Mar 24) to 12.43, marking a decrease of 1.20.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 12.43. This value is within the healthy range. It has decreased from 13.63 (Mar 24) to 12.43, marking a decrease of 1.20.
• For Return on Networth / Equity (%), as of Mar 25, the value is 7.63. This value is below the healthy minimum of 15. It has decreased from 8.85 (Mar 24) to 7.63, marking a decrease of 1.22.
• For Return on Capital Employeed (%), as of Mar 25, the value is 11.43. This value is within the healthy range. It has decreased from 12.50 (Mar 24) to 11.43, marking a decrease of 1.07.
• For Return On Assets (%), as of Mar 25, the value is 6.22. This value is within the healthy range. It has decreased from 7.24 (Mar 24) to 6.22, marking a decrease of 1.02.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.01.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.02. This value is within the healthy range. It has decreased from 0.03 (Mar 24) to 0.02, marking a decrease of 0.01.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.51. It has decreased from 0.58 (Mar 24) to 0.51, marking a decrease of 0.07.
• For Current Ratio (X), as of Mar 25, the value is 4.33. This value exceeds the healthy maximum of 3. It has increased from 4.04 (Mar 24) to 4.33, marking an increase of 0.29.
• For Quick Ratio (X), as of Mar 25, the value is 3.26. This value exceeds the healthy maximum of 2. It has increased from 2.85 (Mar 24) to 3.26, marking an increase of 0.41.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.36. This value is below the healthy minimum of 4. It has increased from 1.25 (Mar 24) to 3.36, marking an increase of 2.11.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 47.17. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 47.17, marking an increase of 47.17.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 30.61. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 30.61, marking an increase of 30.61.
• For Earning Retention Ratio (%), as of Mar 25, the value is 52.83. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 52.83, marking an increase of 52.83.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 69.39. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 69.39, marking an increase of 69.39.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 35.30. This value is within the healthy range. It has decreased from 57.38 (Mar 24) to 35.30, marking a decrease of 22.08.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 17.63. This value is within the healthy range. It has decreased from 30.48 (Mar 24) to 17.63, marking a decrease of 12.85.
• For Enterprise Value (Cr.), as of Mar 25, the value is 23,946.09. It has decreased from 28,818.28 (Mar 24) to 23,946.09, marking a decrease of 4,872.19.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.26. This value exceeds the healthy maximum of 3. It has decreased from 5.09 (Mar 24) to 4.26, marking a decrease of 0.83.
• For EV / EBITDA (X), as of Mar 25, the value is 16.15. This value exceeds the healthy maximum of 15. It has decreased from 19.17 (Mar 24) to 16.15, marking a decrease of 3.02.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.67. This value exceeds the healthy maximum of 3. It has decreased from 5.36 (Mar 24) to 4.67, marking a decrease of 0.69.
• For Retention Ratios (%), as of Mar 25, the value is 52.82. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 52.82, marking an increase of 52.82.
• For Price / BV (X), as of Mar 25, the value is 2.87. This value is within the healthy range. It has decreased from 3.48 (Mar 24) to 2.87, marking a decrease of 0.61.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.67. This value exceeds the healthy maximum of 3. It has decreased from 5.36 (Mar 24) to 4.67, marking a decrease of 0.69.
• For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness